New Insights into Behçet’s Syndrome Metabolic Reprogramming: Citrate Pathway Dysregulation
To date, a major research effort on Behçet’s syndrome (BS) has been concentrated on immunological aspects. Little is known about the metabolic reprogramming in BS. Citrate is an intermediary metabolite synthesized in mitochondria, and when transported into the cytosol by the mitochondrial citrate ca...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2018/1419352 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562714482835456 |
|---|---|
| author | Anna Santarsiero Pietro Leccese Paolo Convertini Angela Padula Paolo Abriola Salvatore D’Angelo Faustino Bisaccia Vittoria Infantino |
| author_facet | Anna Santarsiero Pietro Leccese Paolo Convertini Angela Padula Paolo Abriola Salvatore D’Angelo Faustino Bisaccia Vittoria Infantino |
| author_sort | Anna Santarsiero |
| collection | DOAJ |
| description | To date, a major research effort on Behçet’s syndrome (BS) has been concentrated on immunological aspects. Little is known about the metabolic reprogramming in BS. Citrate is an intermediary metabolite synthesized in mitochondria, and when transported into the cytosol by the mitochondrial citrate carrier—SLC25A1-encoded protein—it is cleaved into acetyl-CoA and oxaloacetate by ATP citrate lyase (ACLY). In induced macrophages, mitochondrial citrate is necessary for the production of inflammatory mediators. The aim of our study was to evaluate SLC25A1 and ACLY expression levels in BS patients. Following a power analysis undertaken on few random samples, the number of enrolled patients was set. Thirty-nine consecutive BS patients fulfilling ISG criteria, and 21 healthy controls suitable for age and sex were recruited. BS patients were divided into two groups according to the presence (active) or absence (inactive) of clinical manifestations. Real-time PCR experiments were performed on PBMCs to quantify SLC25A1 and ACLY mRNA levels. Data processing through the Kruskal-Wallis test and Dunn’s multiple comparison test as post hoc showed higher SLC25A1 and ACLY mRNA levels in BS patients compared to those in healthy controls. Therefore, SLC25A1 and ACLY upregulation suggests that metabolic reprogramming in BS involves the citrate pathway dysregulation. |
| format | Article |
| id | doaj-art-f5c328f1af344cb58d56e226443949c4 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-f5c328f1af344cb58d56e226443949c42025-02-03T01:22:04ZengWileyMediators of Inflammation0962-93511466-18612018-01-01201810.1155/2018/14193521419352New Insights into Behçet’s Syndrome Metabolic Reprogramming: Citrate Pathway DysregulationAnna Santarsiero0Pietro Leccese1Paolo Convertini2Angela Padula3Paolo Abriola4Salvatore D’Angelo5Faustino Bisaccia6Vittoria Infantino7Department of Science, University of Basilicata, Potenza, ItalyRheumatology Department of Lucania, Rheumatology Institute of Lucania (IReL), San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, ItalyDepartment of Science, University of Basilicata, Potenza, ItalyRheumatology Department of Lucania, Rheumatology Institute of Lucania (IReL), San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, ItalyDepartment of Science, University of Basilicata, Potenza, ItalyRheumatology Department of Lucania, Rheumatology Institute of Lucania (IReL), San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, ItalyDepartment of Science, University of Basilicata, Potenza, ItalyDepartment of Science, University of Basilicata, Potenza, ItalyTo date, a major research effort on Behçet’s syndrome (BS) has been concentrated on immunological aspects. Little is known about the metabolic reprogramming in BS. Citrate is an intermediary metabolite synthesized in mitochondria, and when transported into the cytosol by the mitochondrial citrate carrier—SLC25A1-encoded protein—it is cleaved into acetyl-CoA and oxaloacetate by ATP citrate lyase (ACLY). In induced macrophages, mitochondrial citrate is necessary for the production of inflammatory mediators. The aim of our study was to evaluate SLC25A1 and ACLY expression levels in BS patients. Following a power analysis undertaken on few random samples, the number of enrolled patients was set. Thirty-nine consecutive BS patients fulfilling ISG criteria, and 21 healthy controls suitable for age and sex were recruited. BS patients were divided into two groups according to the presence (active) or absence (inactive) of clinical manifestations. Real-time PCR experiments were performed on PBMCs to quantify SLC25A1 and ACLY mRNA levels. Data processing through the Kruskal-Wallis test and Dunn’s multiple comparison test as post hoc showed higher SLC25A1 and ACLY mRNA levels in BS patients compared to those in healthy controls. Therefore, SLC25A1 and ACLY upregulation suggests that metabolic reprogramming in BS involves the citrate pathway dysregulation.http://dx.doi.org/10.1155/2018/1419352 |
| spellingShingle | Anna Santarsiero Pietro Leccese Paolo Convertini Angela Padula Paolo Abriola Salvatore D’Angelo Faustino Bisaccia Vittoria Infantino New Insights into Behçet’s Syndrome Metabolic Reprogramming: Citrate Pathway Dysregulation Mediators of Inflammation |
| title | New Insights into Behçet’s Syndrome Metabolic Reprogramming: Citrate Pathway Dysregulation |
| title_full | New Insights into Behçet’s Syndrome Metabolic Reprogramming: Citrate Pathway Dysregulation |
| title_fullStr | New Insights into Behçet’s Syndrome Metabolic Reprogramming: Citrate Pathway Dysregulation |
| title_full_unstemmed | New Insights into Behçet’s Syndrome Metabolic Reprogramming: Citrate Pathway Dysregulation |
| title_short | New Insights into Behçet’s Syndrome Metabolic Reprogramming: Citrate Pathway Dysregulation |
| title_sort | new insights into behcet s syndrome metabolic reprogramming citrate pathway dysregulation |
| url | http://dx.doi.org/10.1155/2018/1419352 |
| work_keys_str_mv | AT annasantarsiero newinsightsintobehcetssyndromemetabolicreprogrammingcitratepathwaydysregulation AT pietroleccese newinsightsintobehcetssyndromemetabolicreprogrammingcitratepathwaydysregulation AT paoloconvertini newinsightsintobehcetssyndromemetabolicreprogrammingcitratepathwaydysregulation AT angelapadula newinsightsintobehcetssyndromemetabolicreprogrammingcitratepathwaydysregulation AT paoloabriola newinsightsintobehcetssyndromemetabolicreprogrammingcitratepathwaydysregulation AT salvatoredangelo newinsightsintobehcetssyndromemetabolicreprogrammingcitratepathwaydysregulation AT faustinobisaccia newinsightsintobehcetssyndromemetabolicreprogrammingcitratepathwaydysregulation AT vittoriainfantino newinsightsintobehcetssyndromemetabolicreprogrammingcitratepathwaydysregulation |